Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

BACKGROUND: The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription discontinuation and reinitiation in European...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Nephrol
Main Authors: Fuller, Douglas S., Hallett, David, Dluzniewski, Paul J., Fouqueray, Bruno, Jadoul, Michel, Morgenstern, Hal, Port, Friedrich K., Tentori, Francesca, Pisoni, Ronald L.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518810/
https://ncbi.nlm.nih.gov/pubmed/31088377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1355-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki